Daniel Joseph Dorgan - Faculty Biosketch

Daniel Joseph Dorgan, MD

Associate Professor of Clinical Medicine (Pulmonary, Allergy and Critical Care)

Associate Program Director, Adult Cystic Fibrosis Program, University of Pennsylvania

Program Director, Adult Primary Ciliary Dyskinesia Program, University of Pennsylvania

Site Director, Therapeutics Development Network (Site Principal Investigator), Adult Cystic Fibrosis Program, University of Pennsylvania

Director, Advanced Lung Disease Clinical Research Group, University of Pennsylvania

Vice Chief of Clinical Affairs, Division of Pulmonary, Allergy, and Critical Care Medicine 21 University of Pennsylvania

Center Director, Bronchiectasis Care Center Network, University of Pennsylvania

3 5f

Department: Medicine

4 1 b

46 Contact information
40

Harron Lung Center
39 3400 Civic Center Blvd
Philadelphia, PA 19104

2e Office: 215-662-3202
32 Fax: 215-349-8432
24

4 3 3 3 2 4 b 1f

13 Education:
21 7 BS 19 (Biochemistry) c
32 Michigan State University, 1998.
21 7 MD c
2f University of Michigan, 2004.
c

3 3 21

1f Post-Graduate Training
24 5c Resident, Internal Medicine, Columbia University, New York, NY, 2004-2007.
24 76 Fellow, Pulmonary, Allergy & Critical Care, University of Pennsylvania, Philadelphia, PA, 2008-2011.
c

3 25

17 Certifications
28 4f Internal Medicine, American Board of Internal Medicine, 2007.
28 4f Pulmonary Disease, American Board of Internal Medicine, 2010.
28 54 Critical Care Medicine, American Board of Internal Medicine, 2012.
c

3 92 Permanent link
2 29

b6 > Perelman School of Medicine > Faculty > Details a

1e 1d

Description of Clinical Expertise

20 Cystic Fibrosis
16 Bronchiectasis
1a Ciliary Dyskinesia
2a Pulmonary Mycobacterial Infections
23 Chronic Pulmonary Infections
71

Description of Research Expertise

20 Cystic Fibrosis
16 Bronchiectasis
1a Ciliary Dyskinesia
29 Pulmonary Mycobacterial Infections
e 29

Selected Publications

198 Chalmers JD, Burgel P, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fen C, Zhang X, Metersky ML, ASPEN Investigators: Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med 392(16): 1569-1581, Apr 2025.

af Giannini HM, Lee C, Baston C, Dorgan D.: A Diagnostic Sequence. N Engl J Med 388: 1702-1707, May 2023.

138 Hong G, Daniel SG, Lee JJ, Bittinger K, Glaser L, Mattei LM, Dorgan DJ, Hadjiliadis D, Kawut SM, Collman RG.: Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis. J Cyst Fibros 2023.

1cd Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N, McBennett K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Vaughn M, Meltzer EB, Barbier AJ.: Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J Cyst Fibros 2023.

143 O'Dea AL, Feng R, Glaser LJ, Kubrak C, Rubenstein RC, Dorgan DJ, Hadjiliadis D, Kawut SM, Hong G.: The Clinical Association between Aspergillus fumigatus and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis. Ann Am Thorac Soc 2023.

1ae Lee IK, Jacome DA, Cho JK, Tu V, Young AJ, Dominguez T, Northrup JD, Etersque JM, Lee HS, Ruff A, Aklilu O, Bittinger K, Glaser LJ, Dorgan D, Hadjiliadis D, Kohli RM, Mach RH, Mankoff DA, Doot RK, Sellmyer MA: Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim. The Journal of Clinical Investigation 132(18): e156679, Sep 2022.

23d Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, for the PROMISE Study group: Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine 205(5): 529-539, Mar 2022.

2dd Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O’Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH, on behalf of the SIMPLIFY Study Group: Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. The Lancet Respiratory Medicine 2022 Notes: Online first, DOI:https://doi.org/10.1016/S2213-2600(22)00434-9.

1a2 Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, on Behalf of the STOP2 Investigators: A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. American Journal of Respiratory and Critical Care Medicine 65(1): 1295-1305, Dec 2021.

148 Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA: Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation. Journal of Cystic Fibrosis 20(2): 288-294, Mar 2021.

2c

7 1d

2c back to top
26 Last updated: 12/22/2025
34 The Trustees of the University of Pennsylvania c